Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Mango Board | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to test the effect of 12 weeks of 1.5 cups per day of fresh mango on glucose control, insulin resistance, lipids, inflammation, oxidation and body composition in individuals with prediabetes. The main questions it aims to answer are:
Participants will be asked to:
Researchers will compare the 12 weeks participants consume mango to the 12 weeks the participants are not consuming mango to see if there are differences in glycemic indicators, insulin resistance, lipids, inflammation, oxidation and body composition between the two time periods.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mango added to habitual diet | Experimental | Participants will be asked to consume 1.5 cups of mango per day for 12 weeks as part of their habitual diet. |
|
| Habitual diet without mango | No Intervention | Participants will be asked to refrain consuming mangos for 12 weeks while continuing their habitual diet. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mango | Behavioral | 1.5 cups/day of mango for 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| LDL-cholesterol | LDL-cholesterol will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| Total cholesterol | Total cholesterol will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| HDL-cholesterol | HDL-cholesterol will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| Triglycerides | Triglycerides will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| HgbA1c | HgbA1c will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| Fasting blood glucose | Fasting blood glucose will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| Fasting blood insulin | Fasting blood insulin will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| HOMA-IR (Insulin resistance) | Fasting blood glucose and fasting blood insulin will be used to quantify HOMA-IR values. |
| Measure | Description | Time Frame |
|---|---|---|
| C-reactive protein | C-reactive protein will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. | |
| E-selectin | E-selectin will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Celine Heskey, DrPH | Loma Linda University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nutrition Research Center, School of Public Health, Loma Linda University | Loma Linda | California | 92350 | United States |
Not provided
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| D050171 | Dyslipidemias |
| D007333 | Insulin Resistance |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D052439 | Lipid Metabolism Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C501277 | Mangifera indica extract |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fasting blood glucose and insulin will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
| Oxidized LDL-cholesterol | Oxidized LDL-cholesterol will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
| 8-iso-PGF2 alpha | 8-iso-PGF2 alpha will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
| ICAM | ICAM will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
| VCAM | VCAM will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
| TNF-alpha | TNF-alpha will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
| IL-beta | IL-beta will be measured in fasting blood that will be drawn at weeks 0 and 12 of the first phase and the last week of the second phase of the study. |
| Percent body fat | Percent body fat will be measured at weeks 0, 4, 8, 12 of each phase of the study. |
| Fat mass | Fat mass will be measured at weeks 0, 4, 8, 12 of each phase of the study. |
| Lean body mass | Lean body mass will be measured at weeks 0, 4, 8, 12 of each phase of the study. |
| D006946 | Hyperinsulinism |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |